Complete Story


FDA Approves Drug for Rare Form of A.L.S.

The drug targets a genetic cause of a devastating neurological illness

On Tuesday, the Food and Drug Administration (FDA) authorized the first drug for a rare genetic form of the neurological disorder A.L.S., despite uncertainty about the treatment’s effectiveness.

The decision reflects the agency’s push toward greater flexibility in approving treatments for patients with devastating illnesses and few, if any, options.

Biogen, the pharmaceutical company bringing the drug to market, said it would price the drug “within a range comparable to other recently launched A.L.S. treatments.” An A.L.S. therapy approved last year was priced at $158,000 annually.

Please select this link to read the complete article from The New York Times.

Printer-Friendly Version